InMed Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-8.51	-8.16	-7.68	-7.95	-18.6	-10.2
Depreciation & Amortization	0.58	0.53	0.6	0.6	0.51	0.23
Stock-Based Compensation	0.11	0.12	0.14	0.28	0.78	0.61
Other Adjustments	0.09	0.08	0.32	0.36	4.8	0.12
Change in Receivables	0.18	-0.11	-0.09	-0.22	-0.04	0.04
Changes in Inventories	-0.2	0.28	0.07	0.57	-2	-
Changes in Accounts Payable	-0.22	-0.25	0.05	-0.81	-0.81	0.35
Changes in Other Operating Activities	-0.55	-0.26	-0.39	-0.11	-0.22	-0.93
Operating Cash Flow	-7.46	-7.77	-6.99	-7.28	-15.58	-9.79
Capital Expenditures	-	-	-0.01	-0.16	-0.04	-0
Purchases of Investments	-0.04	-0.04	-0.04	-0.04	-	-
Proceeds from Sale of Investments	0.04	0.04	0.04	0.04	-	-
Payments for Business Acquisitions	-	-	-	-0.5	-0.21	-
Other Investing Activities	-	-	-	-	-0.43	-
Investing Cash Flow	-	0	-0.01	-0.66	-0.67	-0
Long-Term Debt Repaid	-	-	-	-	-0.29	-
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-0.29	-
Issuance of Common Stock	4	13.16	5.22	10.68	17.15	12.47
Net Common Stock Issued (Repurchased)	4	13.16	5.22	10.68	17.15	12.47
Other Financing Activities	-0.45	-0.88	-0.56	-	-1.78	-1.62
Financing Cash Flow	8.27	12.27	4.65	10.68	15.07	10.85
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-	0.49
Net Cash Flow	0.81	4.5	-2.34	2.74	-1.19	1.56
Free Cash Flow	-7.46	-7.77	-7	-7.45	-15.62	-9.79
FCF Margin	-231.35%	-157.14%	-152.14%	-180.02%	-1434.03%	-
Free Cash Flow Per Share	-2.22	-7.96	-18.36	-60.81	-557.13	-728.62
Levered Free Cash Flow	-8.91	-7.85	-7.36	-7.86	-21.45	-10.56
Unlevered Free Cash Flow	-9.18	-7.63	-7.87	-8.33	-19.82	-10.3

SEC Filings: 10-K · 10-Q